Dose reduction and contraindication of the novel oral anticoagulant in patients with heart failure and reduced ejection fraction during a follow-up of 27 month. Data from CORONA Trial
22 May 2016 (08:30 - 18:00)
Organised by:
Abstract
Slides
About the speaker
Hospital Valduce, Como (Italy)
9 More presentations in this session
Access the full session
The Event
HEART FAILURE 2016
22 May 2016
08:30 CET
You may be interested in
Congress Presentation
Congress Presentation
Congress Presentation
Congress Session
